Analysis of the Current Situation of Medical Researchers’ Cognition and Attitude towards Ethical Review in China / 中国医学伦理学

Based on the data of a national sampling survey, this paper described and analyzed the understanding, attitude, behavior, and their differences and influencing factors of Chinese medical researchers on ethical review of biomedical research involving human subject. The survey found that researchers with master’s degree or below, working in scientific research institutes or universities, no overseas experience, living in the central region and not serving as committee members have relatively poor acquaintance of "ethical review" ; researchers with the characteristics of male, the younger age, living in the western region, knowing less about "ethical review" , agree more with the view that "ethical review consumes too much time and energy" ; researchers who serve as members of the ethics committee are more likely to participate in scientific research projects that have not passed the ethical review process. Therefore, recommendations are put forward: comprehensively popularizing the training of ethical review, focusing on strengthening the vulnerable groups and regions, strictly implementing ethical review laws and regulations, and strengthening evaluation and supervision, so as to improve the service quality and efficiency of ethical review in multiple directions.

Case analysis and management of research-related injury compensation of drug clinical trials / 中华医学科研管理杂志

Objective:To propose suggestions on the prevention and treatment measures of drug clinical trial research-related injury from the research center perspective, and improve the protection of the rights of human subjects.Methods:Analyze three representative cases of drug clinical trial research-related injury compensation in a hospital, and put forward suggestions for the project management of the research center.Results:By reviewing informed consent forms and clinical trial liability insurance, actively participating in research-related injury treatment and implementation supervision, paying attention to safety information and risk monitoring, ethics committees, clinical trial institutions and investigators can play more proactive roles in protecting the rights and interests of human subjects.Conclusions:The research center could better control the risks of clinical trials and improve the protection of human subjects by strengthening the prevention and treatment measures for clinical trial research-related injury.

Current situation analysis and countermeasures of informed consent and ethical review about clinical trial involving human subject in hospitals / 中华医学科研管理杂志

Objective To explore the current situation of informed consent and ethical review of clinical trial involving human subject in hospitals,and provide related countermeasures.Methods This study searches the website (http://med.wanfangdata.com.cn/Paper),selects "hospital" as the search term,and uses "all fields" as the search criteria.Collected papers were about clinical trial involving human subject that published during Jan.2018 to Feb.2018 in internal medicine,surgery,obstetrics and gynecology,pediatrics.The current situation of informed consent and ethical review of these papers were analyzed from various aspects,including the hospital grades,medical institutions types,clinical research methods,study types,fund projects,periodical category.Results (1) Among 1964 papers,only 538 (27.4％) papers obtained informed consent of subjects and the ethical review approval.(2) There are no significant differences between different hospital grades,and different medical institutions about informed consent and ethical review.(3) Experimental studies focus more on informed consent and ethical review than observational studies.(4) Drug clinical trials focuses more on informed consent and ethical review than non-drug related clinical study.(5) Fund projects focus more on informed consent and ethical review than non-fund pro jects.(6) Papers published in core periodical focus more on informed consent and ethical review than papers published in other periodical.Conclusions Currently,conducting clinical trial involving human subject still does not pay enough attention to the informed consent of subjects and ethical review,more countermeasures are needed to change the current situation and to standardize human clinical trials.

Discussion on the moral responsibilities of investigators from the perspective of human subject protection / 中华医学科研管理杂志

Objective According to the discussion of investigator responsibilities for human subject protection,to provide possible reference for the construction of human subject protection framework calls for more collaboration between investigators and Institutional Review Board (IRB).Methods Systematically analyze the investigator responsibilities during the whole process of research including design,implementation and closure,identify key ethical issues that need attention at different stages.Results Currently,the culture of regulatory compliance,though good for the human subject protection from regulatory perspective,is still not optimal for encouraging more innovative protection from investigator perspectives.Conclusions Human subject protection is not only the responsibility of IRBs,investigators should also be more responsible and bring in more ethical considerations in human subject research.

Introduction and Enlightenment of the Human Subject Protection Program in U.S / 中华医学科研管理杂志

As human subject protection become more and more significant in China,it' s imperative for China to learn more experiences from U.S for which developed a normative and well designed HRPP system during past decades.In this article,we gave a brief introduction of the Human Subject Protection Program at Duke University to help us have a better understanding of the HRPP at institutional level.After which we have further discussion of the status quo and challenges facing in HRPP construction in China,especially,Peking University as an example.

Effect of Bioethics and Safety Act in medical research

The ethics of medical research is an important area of physician ethics. Physicians are called to respect the life, health, and personality of human subjects. In contrast to other ethical fields, physician ethics, including the ethics of medical research, does not rely on the good faith of physicians alone; ethics and the law are intermingled. While respecting international norms related to medical ethics, individual countries have expanded legal interventions into medical research. The United States has regulated the research of human subjects receiving federal funding through the Common Rule. In Korea, legal interventions for human subjects protection have been applied to a limited extent in clinical trials under the Pharmaceutical Affairs Act and the Medical Devices Act in Korea. On January 29, 2004, the Bioethics and Safety Act was enacted, requiring embryo research institutes, gene banks, and gene therapy institutions to establish Institutional Review Boards. On February 1, 2012, the Bioethics and Safety act was completely revised, which was a significant turning point in medical ethics in Korea. Structural differences between the Common Rule of the United States and the Bioethics and Safety Act of Korea are as follows. First, the Bioethics and Safety Act shall be applied regardless of the presence or absence of government funding. Thus the Bioethics and safety act has a more comprehensive and compulsory effect than the Common Rule. Second, under the Bioethics and Safety Act, the Ministry of Health and Welfare has direct supervision over institutional review boards, rather than supervision of the research organization itself. This differs from the Common Rule, which regards the research organization as the counterpart to the government. Third, the Bioethics and Safety Act regulates the study of derivatives of human bodies, in addition to research on human subjects. The Bioethics and Safety Act has the following problems. First, it mandates that researchers, instead of IRBs, record and store data concerning medical research. Second, the Act does not provide a specific definition of "minimal risk". Third, as the Act does not allow the exemption of informed consent of children under the age of 18 even if specific prerequisites are met as in the case of adults, research involving children will atrophy significantly in Korea.

Bioethics and Protection of Personal Information in Experimental Studies / 한국역학회지

Experimental studies involve intervention and manipulation of study elements such as randomization of the participating groups. In general, experimental studies involving human are riskier than observational studies, demanding robust ethical vigilance and compliance among such stakeholders as investigators, sponsors, IRBs and health authorities. Social values of research should be counted as a primary ethical consideration in experimental research. It is unethical to put human subjects into uncertain and risky conditions if the study does not pursue valuable knowledge. Sound scientific design is prerequisite for good ethics. Risk-benefit ratio of the study must be carefully evaluated study. Not only risks from physical harms but also socio-economical and psychological harms from the study should be considered as risk of the study. Risks from the design of the study such as randomization and placebo must be carefully examined. Voluntary informed consent is essential in experimental studies involving human. Human subjects, before they decide to participate in the study, must be informed the followings: risks, benefits, experimental procedures, alternative treatment, compensation for injury, and participants' voluntariness and right to withdraw at anytime. Experimental studies are usually required written consent documentation and full institutional review board (IRB) review. Other elements of experimental research ethics includes special protection for high risk groups and various vulnerable groups, and protection of privacy and confidentiality.

Legal Protection of Subjects' Informed Consent in Clinical Drug Trials / 中国药房

OBJECTIVE:To provide the reference for the improvement of GCP(good clinical practice)regulations and protection of subject's human rights.METHODS:The status quo of the protection of subject's right of informed consent and the elements for the right of informed consent and the existing problems in its practice in China were analyzed.RESULTS & CONCLUSIONS:China should further promote the legislation of clinical trials,reinforce the legal education of researchers,and emphasize the supervision on the illegal tort act.

A Bioethical Viewpoint of Subjects Right Protection / 中国医学伦理学

Fundamental bioethical principle in human subjects experiment is the obligation for investigators to fulfill,and also the right that subjects enjoy.It reflects the right of subjects as follows:right of self-determination,right to be informed,right of privacy,right of life and health,right of life safety,right for prompt rescue,right for compensation,and right of equal treatment.If there are no relevant legal regulations,the right of subjects should be taken into consideration and protected by investigators from a bioethical viewpoint.